Valbenazine
A novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor; is approved for the treatment of tardive dyskinesia.Other Indication Phase 3 Clinical (In Vitro) :Valbenazine exhibits VMAT2 binding affinity in rat striatum and human platelets with Kis of 110 and 150 nM, respectively. (In Vivo) :Valbenazine (10 mg/kg; orally) induces ptosis (primarily an adrenergic response) and increases plasma prolactin primarily a dopaminergic response.
Product Specifications
CAS Number
1025504-45-3
Product Name Alternative
NBI-98854
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
CC (C) CC1CN2CCC3=CC (=C (C=C3C2CC1OC (=O) C (C (C) C) N) OC) OC
Molecular Formula
C24H38N2O4
Molecular Weight
418.5695
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
L-Valine, (2R,3R,11bR) -1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3- (2-methylpropyl) -2H-benzo[a]quinolizin-2-yl ester
Available Sizes
Explore Other Products
Browse additional items from our catalog
FBXO36 CRISPR All-in-one AAV vector set (with saCas9)(Human)
